Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명규 | - |
dc.date.accessioned | 2024-05-17T16:31:26Z | - |
dc.date.available | 2024-05-17T16:31:26Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.other | OAK-34989 | - |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268355 | - |
dc.description.abstract | Objective: This study aimed to assess the potential of PARP inhibitors to prevent cardiotoxicity. Methods: First, a re-analysis and update of a previously published study was conducted. Additional searches were conducted of the PubMed and Cochrane Central Register of Controlled Trials databases on 2 June 2023. After the selection process, the pooled odds ratio (OR) for cardiac adverse events (AEs) was calculated. Second, the FAERS database was examined for 10 frequently co-administered anticancer agents. The reporting odds ratio (ROR) was calculated based on the occurrence of cardiac AEs depending on the co-administration of PARP inhibitors. Results: Seven studies were selected for the meta-analysis. Although not statistically significant, co-administration of PARP inhibitors with chemotherapy/bevacizumab decreased the risk of cardiac AEs (Peto OR = 0.61; p = 0.36), while co-administration with antiandrogens increased the risk of cardiac AEs (Peto OR = 1.83; p = 0.18). A total of 19 cases of cardiac AEs were reported with co-administration of PARP inhibitors in the FAERS database. Co-administration of PARP inhibitors with chemotherapy/bevacizumab significantly decreased the risk of cardiac AEs (ROR = 0.352; 95% confidence interval (CI), 0.194–0.637). On the other hand, for antiandrogens co-administered with PARP inhibitors, the ROR was 3.496 (95% CI, 1.539–7.942). The ROR for immune checkpoint inhibitors co-administered with PARP inhibitors was 0.606 (95% CI, 0.151–2.432), indicating a non-significant effect on cardiac AEs. Conclusion: This study reports that PARP inhibitors show cardioprotective effects when used with conventional anticancer agents. © 2024 by the authors. | - |
dc.language | English | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.subject | cardiac adverse events | - |
dc.subject | combination | - |
dc.subject | FAERS | - |
dc.subject | meta-analysis | - |
dc.subject | PARP inhibitors | - |
dc.title | Cardioprotective Effects of PARP Inhibitors: A Re-Analysis of a Meta-Analysis and a Real-Word Data Analysis Using the FAERS Database | - |
dc.type | Article | - |
dc.relation.issue | 5 | - |
dc.relation.volume | 13 | - |
dc.relation.index | SCIE | - |
dc.relation.index | SCOPUS | - |
dc.relation.journaltitle | Journal of Clinical Medicine | - |
dc.identifier.doi | 10.3390/jcm13051218 | - |
dc.identifier.wosid | WOS:001182787300001 | - |
dc.identifier.scopusid | 2-s2.0-85187702677 | - |
dc.author.google | Han | - |
dc.author.google | Ja-Young | - |
dc.author.google | Seo | - |
dc.author.google | Young-Eun | - |
dc.author.google | Kwon | - |
dc.author.google | Jae-Hee | - |
dc.author.google | Kim | - |
dc.author.google | Jae Hyun | - |
dc.author.google | Myeong Gyu | - |
dc.contributor.scopusid | 김명규(57193132066) | - |
dc.date.modifydate | 20240517135722 | - |